← ANALYST RATINGS · TIPRANKS
Baxter International (BAX): analyst forecast and price target
Analyst consensus
Hold0 Buy4 Hold1 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $26.00, the highest $29.00, the lowest $20.00. The average is +2.8% from the last price of $25.28.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $20.00 | Sell | −20.9% | Initiated | 07.10.26on TipRanks 03:55 | −1.4%next day +0.1% · 5 days +4.4% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $28.00 → $27.00−3.6% | Hold | +6.8% | Reiterated | 05.10.26on TipRanks 07:06 | +2.4%next day 0.0% · 5 days +1.9% | ↗ |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $24.00 → $23.50−2.1% | Hold | −7.0% | Reiterated | 03.10.26on TipRanks 02:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $23.00 → $23.50+2.2% | Hold | −7.0% | Reiterated | 02.10.26on TipRanks 00:05 | — | |
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $24.50 | Hold | −3.1% | Reiterated | 30.09.26on TipRanks 15:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $24.50 | Hold | −3.1% | Reiterated | 30.09.26on TipRanks 15:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $25.00 | Hold | −1.1% | Reiterated | 30.09.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 | Hold | −7.0% | Reiterated | 30.09.26on TipRanks 15:05 | — | |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $20.00 → $28.00+40.0% | Hold | +10.8% | Reiterated | 11.08.26on TipRanks 08:50 | −0.3%next day −2.6% · 5 days −5.6% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $26.00 | Hold | +2.8% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | −1.0%next day +1.4% · 5 days −1.1% | ↗ |
| Pito Chickering★★★★★★★★★★#1500 · hits 61% · avg +9.8% | Deutsche Bank | $20.00 → $27.00+35.0% | Hold | +6.8% | Reiterated | 31.07.26on TipRanks Aug 6 18:00 | −2.9%next day +6.0% · 5 days +1.8% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $24.00 → $29.00+20.8% | Hold | +14.7% | Reiterated | 31.07.26on TipRanks 08:01 | −2.9%next day +6.0% · 5 days +1.8% | ↗ |
| Unknown Analyst | Wells Fargo | $19.00 → $23.00+21.1% | Hold | −9.0% | Assigned | 31.07.26on TipRanks 07:38 | −2.9%next day +6.0% · 5 days +1.8% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $24.00 → $28.00+16.7% | Hold | +10.8% | Reiterated | 31.07.26on TipRanks Jul 28 07:00 | +4.2%next day +3.2% · 5 days +12.2% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $19.00 → $25.00+31.6% | Hold | −1.1% | Assigned | 28.07.26on TipRanks 08:23 | +4.2%next day +3.2% · 5 days +12.2% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $19.00 → $21.00+10.5% | Hold | −16.9% | Assigned | 15.07.26on TipRanks 06:30 | +1.2%next day +6.0% · 5 days −0.9% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $22.00 → $24.00+9.1% | Buy | −5.1% | Reiterated | 06.07.26on TipRanks 08:50 | −1.2%next day +1.7% · 5 days +0.2% | ↗ |
| Steven Silver★★★★★★★★★★#2962 · hits 80% · avg +22.7% | Argus Research | — | Hold | — | Reiterated | 08.05.26on TipRanks May 11 10:15 | +2.0%next day −2.8% · 5 days −4.0% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $21.00 → $19.00−9.5% | Hold | −24.8% | Reiterated | 12.02.26on TipRanks 16:00 | +5.7%next day +4.6% · 5 days +7.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Baxter International
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.90 at a price of $24.00 (+7.9%); now: $25.89 at $25.28 (+2.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 3 | 2 | 1 | 1 | 1 | 0 |
| Hold | 4 | 4 | 6 | 5 | 4 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.52 (from $0.50 to $0.54). Last quarter: $0.56.
Sales
Next quarter’s sales estimate — $2.9B (from $2.9B to $2.9B). Last quarter: $3.0B.
Best top-analyst consensus in the sector · Healthcare
About Baxter International
- CEO: Andrew Hider
- Employees: 37,500
- One Baxter Parkway, Deerfield, IL, 60015, US
- www.baxter.com
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 10
Data from the stock’s TipRanks forecast page, read 2 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗